PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION

Clinical trials for PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION explained in plain language.

Never miss a new study

Get alerted when new PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION trials appear

Sign up with your email to follow new studies for PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Targeted drug duo tested for Tough-to-Treat prostate cancer

Disease control Terminated

This study tested whether combining two drugs, apalutamide and abiraterone acetate, could better control advanced prostate cancer that had spread and stopped responding to standard hormone therapy. It aimed to see if this combination could slow the cancer's growth in men whose tu…

Matched conditions: PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 18, 2026 14:41 UTC

PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION

Get alerted when new PROSTATE ADENOCARCINOMA WITHOUT NEUROENDOCRINE DIFFERENTIATION trials appear

Targeted drug duo tested for Tough-to-Treat prostate cancer